These programmes are non-promotional and sponsored by Sanofi and Regeneron Pharmaceuticals.
This content is intended for HCPs.
The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this presentation.
The content contained in these programmes was jointly developed by the speakers, Sanofi, and Regeneron, and is not eligible for continuing medical education (CME) credits.
Sanofi and Regeneron Pharmaceuticals do not recommend the use of their products in any manner inconsistent with that described in the full prescribing information available in your country. Before prescribing any product, always refer to the prescribing information in the summary of product characteristics available in your country.
Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management
Klaus Rabe, Paola Rogliani, and Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in chronic obstructive pulmonary disease (COPD). They provide insights into the genetic association of IL-33 with COPD, discuss preclinical findings, and review ongoing clinical research targeting IL-33 in COPD.
Learning Objectives:
- Discuss the complexity of inflammatory pathways in COPD and different phenotypes.
- Provide evidence on the genetic association of IL-33 and COPD and early preclinical results.
- Discuss outcomes of IL-33 targeting and review the ongoing research in the science behind IL-33 in COPD.
Speakers
Klaus Rabe (Chair)1
Stephanie Christenson2
Paola Rogliani3
1. LungenClinic Grosshansdorf, Germany
2. University of California, San Francisco, California, USA
3. Università di Roma ‘Tor Vergata’, Rome, Italy
A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation
Henrik Watz, Mona Bafadhel, and Alberto Papi discuss the pathophysiology of COPD with type 2 inflammation and review current and emerging biologic therapies.
Learning Objectives:
- Link the underlying drivers of COPD with type 2 inflammation to cumulative patient burden.
- Communicate the differential roles of type 2 cytokines and mediators as markers or drivers of disease in COPD with type 2 inflammation.
- Understand the current and emerging therapeutic options for COPD with type 2 inflammation.
Speakers
Henrik Watz (Chair)4
Mona Bafadhel5
Alberto Papi6
4. LungenClinic Grosshansdorf Velocity Clinical Research, Grosshansdorf, Germany
5. King’s College London, UK
6. University of Ferrara, Italy
MAT-GLB-2407324 – 1.0 – 11/2024
